Apple’s Fitness+ may launch soon to delight fitness buffs

Those who wish to include some awesome exercise routines into their daily schedules may have a new tech-savvy way to do so. With Apple Fitness+ expected to launch soon, health buffs may have everything they need right in their phones.



Apple Fitness Plus Service


© Photo: Pixabay
Apple Fitness Plus Service

In Apple’s September “Hi-Speed” event, the company announced that they are developing the Fitness+ service, which was set to launch by the end of 2020. With only a couple of weeks left before everyone will be saying goodbye to 2020, many are expecting, as MacWorld reported, that the service will be launched by the tech giant anytime now. This is not just a fictional narrative since there seems to be clues that were provided by Apple.

For one, there is an ongoing campaign on Instagram, which promotes Fitness+. A number of trainers have already published posts that use the hashtag #closeyourrings. It does not end there as the posts were tagging @applefitnessplus.

The trainers who were using the hashtag were inside the studio doing fitness workouts. Many noticed that the training sessions for Fitness+ were recorded from the same studio where the trainers were.

Although it is still unknown as to when exactly Apple will make Fitness+ available, there are already traces of the service, which could be found in watchOS 7.2 of the Apple Watch. It is still in beta phase though. It is also expected to launch in English-speaking countries only.

One of the popular trainers who posted about it on Instagram is Kim Ngo (@itskimngo). “I can’t wait for you to try @applefitnessplus! There’s something for everyone! And I’m adding some spice and all things nice with HIIT workouts – beat drops included ?? #CloseYourRings.”

Another is Amir Ekbatani (@amiritemusic) who also tagged the @applefitnessplus team and expressed excitement about the service.

“Let me tell you this: I have grown more in 2020 than in all of the years of my life, and I have the @applefitnessplus team and vision to thank…I’m counting the minutes until I can train and get stronger with you. I’ve never been more ready to inspire and lead by example. #CloseYourRings



a woman looking at the camera: Apple Fitness+ service to launch soon. Photo: Pixabay


© Photo: Pixabay
Apple Fitness+ service to launch soon. Photo: Pixabay

Source Article

Read more

Sidra’s Precision Medicine symposium ready for launch

Sidra Medicine has announced that it is all set to host the fifth edition of its flagship ‘Precision Medicine and Functional Genomics 2020’ (PMFG 2020). The symposium will be held online from December 5-7, providing resourceful ‘remote learning’ opportunities on account of the current pandemic restrictions, according to a press statement.
Attendees to PMFG 2020 will receive 14.25 hours credits for learning as approved by the Qatar Council of Healthcare Practitioners. The conference is being billed as one of the major scientific symposiums from the Middle East, dedicated to covering topics relevant to the current pandemic as well as the importance of precision medicine, the statement notes.
Registered attendees will be able to access various sessions – from live and on-demand programming – and hear from notable local and international speakers. PMFG 2020 will dedicate a special session on Covid-19, which sheds light on the testing and treatment strategies that are now in place, including examples of recent methods developed and enhanced in Qatar.
“Precision Medicine is a key focus area for our conference programme and indeed, for Qatar. Sidra Medicine has been working closely with our local partners to build capacity in this area in recent years, and considering growing global interest in making precision medicine a reality for patients, we are excited to share early success stories. PMFG 2020 will provide an engaging platform for speakers to present best practices, discuss case studies and explore future opportunities. It will also be a forum to present innovations using precision technologies, in tackling a variety of ongoing health challenges such as diabetes, cancer and Covid-19,” said Dr Khalid Fakhro, chief research officer, Sidra Medicine.
PMFG 2020 will feature global and local thought leaders, including Prof Sir Mark Caulfield – chief scientist, Genomics England, UK, who will talk about the ‘100,000 Genomes Project’ and health transformation. Other notable speakers include Prof Adolfo Garcia-Sastre, professor of Medicine and Microbiology, The Icahn School of Medicine, US, discussing the development of Covid-19 vaccines; Dr Stephen Hunger, chief, Division of Paediatric Oncology, and director, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, US, discussing implementing new precision medicine and immunotherapy strategies in paediatric acute lymphoblastic leukaemia.
In addition, Dr Alan Shuldiner, vice-president, Regeneron Pharmaceuticals, Inc, New York, US, will discuss ‘The Regeneron Genetics Center at 1 million exomes: What have we learned’; in addition to Dr Virginia Pascual, Ronay Menschel Professor of Paediatrics, director, Drukier Institute for Children’s Health, Weill Cornell Medicine – New York, US, talking about ‘A Personalised Approach to Understand Systemic Lupus Erythematosus Heterogeneity’.
To register, preview the full agenda and see the speakers’ list, one has to visit https://www.sidra.org/pmfg.

Read more

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read more

Anna Victoria’s Postpartum Journey Inspired Her to Launch New Programs On Her Fitness App

2020 has been a big year for Anna Victoria. On the personal front, after a two-year battle with infertility, the Fit Body Guides creator welcomed her first child, Aurora Vittoria Ferretti, in August.



a group of people posing for a photo: Anna Victoria


© Provided by Shape
Anna Victoria

But Victoria has been busy at work, too. She’s been developing a series of updates to her Fit Body app, including the launch of a pregnancy workout program and the introduction of three new trainers.

Victoria says being a first-time mom motivated her to bring something new to the Fit Body app that would specifically cater to her fellow mamas. “You hear about how hard being a mom is, but you really can’t comprehend it until you go through it yourself,” she tells Shape. “There are so many emotions and so many new things you have to learn — and in the midst of it all, you’re constantly feeling like you’re doing something wrong.”

In addition to emotional ups and downs, Victoria says she’s had some physical challenges during her postpartum journey as well. One week after her (unplanned) C-section in August, she says, she couldn’t even sit up on her own. “It took me two weeks to walk without pain,” she shares. “When you have a newborn, you don’t expect to be going through that. It’s a lot to juggle, which has, at times, been very hard.” (Related: 7 Moms Share What It’s Really Like to Have a C-Section)



a group of people posing for a photo: Along with a new pregnancy-focused workout program, the trainer will also be welcoming three new trainers to the Fit Body app.


© Anna Victoria
Along with a new pregnancy-focused workout program, the trainer will also be welcoming three new trainers to the Fit Body app.

It wasn’t until she was three weeks postpartum that Victoria started feeling more like herself again, she says. “Every week since then, I’ve gotten exponentially better,” she explains.

But when she was cleared by her doctor to work out again in September at around six weeks postpartum, Victoria knew she wasn’t physically capable of diving back in just yet. “I couldn’t even think about it,” she says. “I know my body and I just wasn’t ready.”

Instead, from weeks 6-8, Victoria says she focused on breathing techniques to start feeling in tune with her body again. “I felt like building a mind-muscle connection with my core was a good place to start,” she says. (Related: Fitness Influencer Anna Victoria Fights Back Against Pregnancy Workout Shaming)

The following week, Victoria started inching her way back into a workout routine. Her first “true” workout, she says, was a beginner-level, low-impact lower-body workout from her Fit Body app. “I even ditched the weights, but I still couldn’t walk for a week [after that first workout],” she admits. “I didn’t expect to be that sore! It was so hard.”

The experience was not only humbling for Victoria, a seasoned trainer, but it also inspired her to bring more pregnancy-, postpartum-, and beginner-friendly workouts to the Fit Body app — plus a new group of trainers to teach them.

What to Expect From the New Fit Body App Updates

If

Read more

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian

Read more

VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center

SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.

Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group
Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group

As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.

VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center 

The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.

Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”

George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”

Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”

VeChain Facilitating Digital Transformation To Improve Public Health

In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.

By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife

Read more